Eledon Pharmaceuticals (ELDN) Cash from Investing Activities (2013 - 2026)

Eledon Pharmaceuticals' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at $6.0 million for Q1 2026.

• Quarterly Cash from Investing Activities rose 53.03% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.9 million (up 116.87% YoY) and the FY2025 annual result came in at $10.8 million, up 115.35% from the prior year.
• Cash from Investing Activities was $6.0 million for Q1 2026 at Eledon Pharmaceuticals, up from -$20.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $15.0 million in Q2 2025 and bottomed at -$47.4 million in Q4 2024.
• A 4-year average of -$6.2 million and a median of $3.9 million in 2025 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities plunged 570.25% — and 2025, when it soared 196.9%.
• Eledon Pharmaceuticals' Cash from Investing Activities stood at $10.1 million in 2023, then plunged by 570.25% to -$47.4 million in 2024, then jumped by 56.81% to -$20.5 million in 2025, then soared by 129.11% to $6.0 million in 2026.
• Business Quant data shows ELDN's Cash from Investing Activities at $6.0 million in Q1 2026, -$20.5 million in Q4 2025, and $12.4 million in Q3 2025.